Arabic Arabic English English French French German German
dark

Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business

Kedrion to acquire, for a total of USD 17M , 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Liminal to receive up to 70% of net proceeds from sale of Priority Review Voucher for which it is potentially eligible with possible FDA approval for Ryplazim ® Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Tips for Managing Constipation with Crohn’s Disease

Next Post

DKSH acquires Hahn Healthcare

Related Posts
Total
0
Share